Indeed, treatment of multiple myeloma-bearing mice with soluble RANKL to stimulate osteoclast formation and resorption resulted in a significant decrease in the number of dormant tumor cells in the bone marrow. The gene discussed is TNFSF11; the disease is plasma cell myeloma.